Newer Formulations of Risperidone: Role in the Management of Psychotic Disorders

TY - JOUR

T1 - Newer Formulations of Risperidone: Role in the Management of Psychotic Disorders

AU - Clark, Ivana

AU - Taylor, David

PY - 2020/8/1

Y1 - 2020/8/1

N2 - Antipsychotic long-acting injections improve relapse prevention in psychotic disorders. Three new risperidone formulations have been developed that offer advantages over currently available risperidone-based long-acting injections. Risperidone ISM ® is a monthly intramuscular injection that does not require loading doses or concurrent oral risperidone. RBP-7000 is a monthly subcutaneous injection not requiring loading or oral supplementation. BB0817 is a 6-monthly implant of risperidone injected subcutaneously. All three preparations have been shown to be effective and well tolerated in clinical trials. A fourth formulation (TV-46000), which can be given subcutaneously every 1 or 2 months, has recently begun trials.

AB - Antipsychotic long-acting injections improve relapse prevention in psychotic disorders. Three new risperidone formulations have been developed that offer advantages over currently available risperidone-based long-acting injections. Risperidone ISM ® is a monthly intramuscular injection that does not require loading doses or concurrent oral risperidone. RBP-7000 is a monthly subcutaneous injection not requiring loading or oral supplementation. BB0817 is a 6-monthly implant of risperidone injected subcutaneously. All three preparations have been shown to be effective and well tolerated in clinical trials. A fourth formulation (TV-46000), which can be given subcutaneously every 1 or 2 months, has recently begun trials.

UR - http://www.scopus.com/inward/record.url?scp=85085564034&partnerID=8YFLogxK

U2 - 10.1007/s40263-020-00735-3

DO - 10.1007/s40263-020-00735-3

M3 - Review article

SN - 1172-7047

VL - 34

SP - 841

EP - 852

JO - CNS Drugs

JF - CNS Drugs

IS - 8

ER -